Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
REVENUE:        
Product revenue, net $ 2,822 $ 3,989 $ 7,512 $ 3,989
COSTS AND EXPENSES:        
Cost of revenue 1,555 2,374 6,582 2,374
Research and development 9,114 21,050 31,675 69,535
Selling, general and administrative 7,707 8,712 24,519 23,131
Asset impairment charges 58,957
  18,376 32,136 121,733 95,040
Operating loss (15,554) (28,147) (114,221) (91,051)
Grant income 1,668 0 1,668 0
Gain on change in fair value of warrant liabilities 6,150
Other (expense) income, net (327) 172 (1,525) 1,715
Net loss available to common stockholders $ (14,213) $ (27,975) $ (107,928) $ (89,336)
Net loss per common share, basic $ (0.23) $ (38.63) $ (4.66) $ (143.47)
Net loss per common share, diluted $ (0.23) $ (38.63) $ (4.66) $ (143.47)
Weighted average common shares outstanding, basic 62,122,283 724,190 23,136,172 622,684
Weighted average common shares outstanding, diluted 62,122,283 724,190 23,136,172 622,684